Full Press Release Details
Accessibility: Skip TopNav
Summit Corporation PLC : Notice of Results
September 04, 2012 02:00 ET
Summit Therapeutics plc
Summit Therapeutics plc
Summit Corporation plc
('Summit' or 'the Company')
NOTICE OF INTERIM RESULTS
Oxford, UK, 4 September 2012 - Summit (AIM: SUMM), a UK drug discovery company, announces that it will be releasing its interim financial results for the six months ended 31 July 2012 on 6 September 2012.
For more information, please contact:
| Summit Glyn Edwards / Richard Pye | Tel: +44 (0)1235 443 951 |
| Singer Capital Markets (Nominated Adviser and Joint broker) Shaun Dobson / Claes Spång | Tel: +44 (0)203 205 7500 |
| Hybridan LLP (Joint broker) Claire Louise Noyce / Deepak Reddy | Tel: +44 (0)207 947 4350 |
| Peckwater PR (Financial public relations, UK) Tarquin Edwards | Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |
| MacDougall Biomedical Communications (U.S. media contact) Michelle Avery | Tel: +1 781-235-3060 |
Summit is an Oxford, UK based drug discovery Company with a portfolio of drug programme assets and a drug discovery platform called Seglins(TM) technology. Summit's programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy, C. difficile infection and a group of neurodegenerative diseases called tauopathies. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com.